New stock news | Savior Group submits application to Hong Kong Stock Exchange GEM, ranked first in the Hong Kong mask and respirator market.

According to the disclosure by the Hong Kong Stock Exchange on June 16, Savior Group Limited (referred to as Savior Group) submitted its listing application to the Hong Kong Stock Exchange GEM Board, with BAIHUI Capital as its exclusive sponsor. Company Profile The prospectus shows that the company is a Hong Kong-based manufacturer and multi-channel distributor of personal protective and healthcare products with a focus on the sale of disposable masks under the SAVEWO brand. According to a Frost & Sullivan report, the company ranked first in the Hong Kong mask and respirator market with a market share of approximately 14.1% in the 2026 fiscal year, and ranked third in the Hong Kong self-testing respiratory rapid antigen test market in the 2026 fiscal year with a market share of approximately 11.4%. During the reporting period, the company generated most of its revenue from the design, manufacturing, and sale of its in-house brand Savewo disposable masks. With a comprehensive research and development, design and manufacturing platform, as well as product commercialization and scaling capabilities, the company has expanded its product line to include rapid antigen test kits, mobility aids, and other healthcare-related products. The company's name, Savewo, is derived from Save the World, reflecting the company's founding purpose of safeguarding health through innovative personal protective and healthcare products. The company's operations cover (i) market research and product development, (ii) procurement, (iii) manufacturing, (iv) sales, and (v) customer feedback collection. The company manufactures certain in-house brand products in its production facility in Tsuen Wan, Hong Kong, and procures materials from third-party suppliers based on the company's specifications and/or proprietary formulas, or outsources the production of some in-house brand products through qualified subcontractors. Financial Information Revenue For the fiscal years ended March 31, 2025, and March 31, 2026, the company's revenue was HK$73.213 million and HK$75.543 million, respectively. Profit For the fiscal years ended March 31, 2025, and March 31, 2026, the company's net profits for the year were HK$8.267 million and HK$16.781 million, respectively. Industry Overview From a low baseline of HK$102 million in the 2020 fiscal year before the epidemic, the overall personal protective and diagnostic market has undergone significant transformation, experiencing a strong compound annual growth rate of 34.9% from the 2020 fiscal year to the 2026 fiscal year. Driven by strict government regulations, the mask and respirator segment recorded HK$3.086 billion in the 2022 fiscal year, sharply declining to HK$634 million in the 2025 fiscal year and HK$480 million in the 2026 fiscal year. However, during the period from the 2020 fiscal year to the 2026 fiscal year, the segment still achieved a strong compound annual growth rate of 29.5%, indicating continued increase in baseline demand compared to pre-2020 levels. Looking ahead, with continued seasonal flu awareness and support for established hygiene habits after the epidemic, the market is expected to grow steadily at a rate of 3.9% from the 2027 fiscal year, reaching HK$560 million by the 2031 fiscal year. It is worth noting that consumer behavior is shifting towards high-end products. Although overall sales volume is low, buyers are increasingly prioritizing high filtration efficiency, breathability, and attractive design, creating continuous value creation opportunities for innovative brands. Starting from virtually zero in the 2020 fiscal year, the retail market for self-testing respiratory rapid antigen test kits reached HK$87.8 million in the 2021 fiscal year, followed by extreme fluctuations, rising from HK$291 million in the 2022 fiscal year to a peak of HK$6.352 billion in the 2023 fiscal year, influenced by severe waves of infections and mandatory testing requirements. With the end of these mandatory requirements, sales plummeted to HK$199 million in the 2025 fiscal year, resulting in a negative compound annual growth rate of 17.8% from the 2022 fiscal year to the 2026 fiscal year, as consumers used existing household stocks rather than making new retail purchases. The segment is expected to normalize on a lower baseline, used for occasional symptom testing, and is projected to reach HK$187 million by the 2031 fiscal year, with a compound annual growth rate of 6.0% from the 2027 fiscal year onwards. Importantly, the epidemic has permanently established consumer familiarity with home diagnostics, integrating these tools into daily household health management and laying a solid foundation for future retail demand for a wider range of multi-health screening test kits. Board of Directors Information As compiled, the company's board of directors will consist of five members, including two executive directors and three independent non-executive directors. The board is responsible for and has general powers to manage and operate the group's business. Equity Structure Following compilation and completion (excluding any shares that may be issued and any options that may be granted under the compilation exercise), in accordance with the joint action confirmation and reference to Part XV of the Securities and Futures Ordinance, WaterFun (wholly owned by Ms. Cai), Ms. Cai, IndexPI (wholly owned by Mr. Ding), and Mr. Ding will each have the right or be deemed to have the right to exercise or control the exercise of the total issued share capital of the compilation. Mr. Huang, as Ms. Cai's spouse, is also deemed to have an interest in the shares held by Ms. Cai under Part XV of the Securities and Futures Ordinance. Therefore, WaterFun, Ms. Cai, IndexPI, Mr. Ding, and Mr. Huang will collectively constitute a group of controlling shareholders of the company at the time of compilation. Intermediary Team Exclusive Sponsor: BAIHUI Capital Limited; Legal Counsel: HuaShang (Hong Kong) Solicitors, OJA Solicitors; Legal Counsel of the Exclusive Sponsor: CLKW Lawyers LLP; Auditors and Reporting Accountants: Ernst & Young Limited; Compliance Adviser: BAIHUI Capital Limited; Internal Control Adviser: M00 Robust Evolution Limited; Industry Consultant: Frost & Sullivan Limited; Senior Counsel: Tan Junjie, Denis Changs Chambers.